Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma [Hematologic Malignancy]

Conclusion
Enzastaurin did not significantly improve DFS in patients with high-risk DLBCL after achieving complete response to R-CHOP. Achievement of a complete response may have abrogated the prognostic significance of cell of origin by immunohistochemistry.

Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Crump, Leppa, Fayad, Lee, Di Rocco, Ogura, Hagberg, Schnell, Rifkin, Mackensen, Offner, Pinter-Brown, Smith, Tobinai, Yeh, Hsi, Nguyen, Shi, Hahka-Kemppinen, Thornton, Lin, Kahl, Schmitz, Savage, Habermann Tags: Chemotherapy, Translational Oncology Hematologic Malignancy Source Type: research